Related Experiment Videos
Safe use of platelet GP IIb/IIIa inhibitors
J J Ferguson1, D J Kereiakes, A A Adgey
1Texas Heart Institute, Houston 77225-0345, USA.
Insights
Abciximab, a glycoprotein IIb/IIIa receptor inhibitor, significantly reduces adverse events in high-risk coronary interventions. Safety concerns, like bleeding, can be mitigated with specific strategies, improving patient outcomes.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Abciximab is a glycoprotein IIb/IIIa receptor inhibitor used in high-risk percutaneous coronary interventions.
- It is widely used in the United States and Europe, significantly reducing mortality and myocardial infarction.
Purpose of the Study:
- To review clinical progress of abciximab.
- To formulate recommendations for enhancing its safety.
- To identify future research directions for glycoprotein IIb/IIIa inhibitors.
Main Methods:
- Expert consensus meeting in Davos, Switzerland.
- Review of clinical trials and post-marketing experience.
- Analysis of strategies to mitigate bleeding risk.
Main Results:
- Abciximab significantly reduces death, nonfatal myocardial infarction, and revascularization needs.
- Bleeding risk can be substantially reduced by using low-dose heparin, early sheath removal, and proper vascular access site care.
- Recommendations for enhancing safety in various clinical situations were provided.
Conclusions:
- Specific strategies can effectively reduce bleeding complications associated with abciximab.
- Continued research is needed to optimize the use of potent antiplatelet agents like abciximab.
Abstract:
The platelet membrane glycoprotein IIb/IIIa receptor inhibitor abciximab is used for the treatment of patients undergoing high-risk percutaneous coronary interventions and is used in approximately one third of coronary interventions in the United States and a growing number of procedures in Europe. Recent clinical trials have shown that this potent antiplatelet agent significantly reduces the incidence of death and nonfatal myocardial infarction and the need for revascularization. With expanding experience since the commercial release of abciximab in February 1995, several strategies to enhance the safety of abciximab have emerged. In particular, new data confirm that the risk of bleeding-identified as a concern in the original EPIC trial-can be substantially reduced through the use of low-dose adjunctive heparin, early sheath removal, and fastidious postprocedure vascular access site care. Other recommendations for enhancing the safety of potent antiplatelet agents in a variety of clinical situations are provided. The following article reflects insights regarding the safety of glycoprotein IIb/IIIa inhibitors expressed by a group of international experts convened in Davos, Switzerland, February 16, 1997 This report attempts to review clinical progress to date, formulate recommendations, and map out potentially fruitful lines of inquiry for future investigation.